▲ +17.54% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $52.80, with a high forecast of $70.00 and a low forecast of $35.00. The average price target represents a 17.54% upside from the last price of $44.92.
The current consensus among 4 contributing investment analysts is to buy stock in Castle Biosciences.
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.